Pharmaceuticals Europe

Europe MASH (NASH) Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Europe MASH (NASH) Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Stage, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $331.0 Mn Placeholder estimate
Estimate 2025 $465.3 Mn 19.2% of the global market
Projected 2034 $9.99 Bn 2,047.2% Adds $9.53 Bn over 9 forecast years
CAGR 2025–2034 40.6% Faster than 99% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Europe is 19.23% of the global market.
  • Among regions, the largest is North America at $1.10 Bn.
  • Fastest growing: APAC at 43.6% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$9.53 Bn total, 2026–2034

Year-by-year market size, 2024–2034
MASH (NASH) Therapeutics Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $331.0 Mn — —
2025 (base) $465.3 Mn +$134.4 Mn —
2026 (forecast) $654.3 Mn +$188.9 Mn +40.6%
2027 (forecast) $919.9 Mn +$265.6 Mn +97.7%
2028 (forecast) $1.29 Bn +$373.5 Mn +177.9%
2029 (forecast) $1.82 Bn +$525.1 Mn +290.8%
2030 (forecast) $2.56 Bn +$738.3 Mn +449.4%
2031 (forecast) $3.59 Bn +$1.04 Bn +672.5%
2032 (forecast) $5.05 Bn +$1.46 Bn +986.2%
2033 (forecast) $7.11 Bn +$2.05 Bn +1,427.2%
2034 (forecast) $9.99 Bn +$2.89 Bn +2,047.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe MASH (NASH) Therapeutics Market Analysis at a glance
Market size, 2025$465.3 Mn placeholder estimate
Forecast, 2034$9.99 Bn placeholder estimate
Growth (CAGR), 2025–203440.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledMASH Drugs
SegmentsDrug class, stage and end user (see all)
Key playersMadrigal Pharmaceuticals, Novo Nordisk A/S, Akero Therapeutics, 89bio, Inventiva and 1 more (see all)
Regulator in EuropeEMASource: European Medicines Agency. Checked 14 Nov 2026.
Active clinical trials72 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe MASH (NASH) Therapeutics Market Analysis Executive Summary

MASH therapeutics treat metabolic dysfunction-associated steatohepatitis, a serious fatty liver disease that can lead to cirrhosis and liver failure.

Key segments of the MASH (NASH) Therapeutics market include drug class (THR-beta Agonists, GLP-1 Agonists and FGF21 Analogs) and stage (Fibrosis Stage F2-F3 and Compensated Cirrhosis).

Bar chart: Europe MASH (NASH) Therapeutics market size, 2024–2034, placeholder estimates. $331.0 Mn in 2024, $465.3 Mn in 2025 and $9.99 Bn in 2034, 40.6% CAGR.
Europe MASH (NASH) Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe MASH (NASH) Therapeutics Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the MASH (NASH) Therapeutics market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the MASH (NASH) Therapeutics market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the MASH (NASH) Therapeutics market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for MASH (NASH) Therapeutics Market in Europe

The MASH (NASH) Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for MASH (NASH) Therapeutics Market in Europe

MASH (NASH) Therapeutics in Europe: rules, payment and research

In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).⁠[1] In the countries we cover here, medicines are approved by ANSM (France)⁠[2], BfArM (Germany)⁠[3], AIFA (Italy)⁠[4], Ministry of Health (Russia)⁠[5], AEMPS (Spain)⁠[6] and MHRA (UK)⁠[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[8] ClinicalTrials.gov lists 72 studies on MASH (NASH) Therapeutics that are recruiting, active or about to start in Europe.⁠[9]

[1] European Medicines Agency. Checked 14 Nov 2026.

[2] ANSM, French medicines agency. Checked 14 Nov 2026.

[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.

[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[8] European Commission, health technology assessment. Checked 14 Nov 2026.

[9] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for MASH (NASH) Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in MASH (NASH) Therapeutics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

MASH (NASH) Therapeutics in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the MASH (NASH) Therapeutics market in Europe?
Placeholder estimate: about $465.3 Mn in 2025, rising to about $9.99 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the MASH (NASH) Therapeutics market in Europe growing?
Placeholder estimate: about 40.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the MASH (NASH) Therapeutics market report cover?
The report splits the market by drug class (THR-beta Agonists, GLP-1 Agonists, FGF21 Analogs, PPAR Agonists), stage (Fibrosis Stage F2-F3, Compensated Cirrhosis) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the MASH (NASH) Therapeutics market?
Key players include Madrigal Pharmaceuticals, Novo Nordisk A/S, Akero Therapeutics, 89bio, Inventiva and Boston Pharmaceuticals.
What is driving the MASH (NASH) Therapeutics market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the MASH (NASH) Therapeutics market.
Who regulates MASH (NASH) Therapeutics in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on MASH (NASH) Therapeutics are running in Europe?
72 studies are recruiting, active or about to start in Europe, counted across the 6 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on MASH (NASH) Therapeutics?
PubMed lists 16 papers on MASH (NASH) Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Europe

See all

Related on liver health and obesity

See the topic